Launch week offerEnds in00h00m00s

annual Promonthly Pro

Daniel G Fuster

Has grant

Full Professor (Ordinarius)

University of Bern

Switzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Switzerland Professors in Biochemistry Biochemistry professors in Switzerland

About

Daniel G. Fuster is an Assistant Professor at Bern University Hospital in Switzerland. His research focuses on kidney stone disease, including its risk factors, pathophysiology, and management, as well as related topics such as nephrectomy in genetic kidney disorders and incidental findings in imaging studies. He has authored numerous articles addressing both clinical implications and innovative treatment approaches for patients with kidney stones.

Recent Grants

Grant: Open

Randomized placebo-controlled trial to assess efficacies of EMPAgliflozin and personalized dietary counseling for kidney STONE prevention in patients with calcium kidney stones (EMPASTONE)

Open Date: 2025-07-01

Close Date: 2030-06-01

Grant: Open

Unraveling the role of NHA2 and GPP130 in Golgi function and insulin secretion in pancreatic β-cells

Open Date: 2024-10-01

Close Date: 2028-09-30

Grant: Close

Randomized placebo-controlled trial to assess the efficacy of EMPAgliflozin and professional dietary counselling for kidney STONE recurrence prevention in patients with calcium kidney stones (EMPASTONE)

Open Date: 2024-07-01

Close Date: 2024-10-31

Grant: Open

Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Secondary Prevention of Kidney Stones: a Randomized, Double-blind, Crossover Trial (INDAPACHLOR Trial)

Open Date: 2024-04-01

Close Date: 2028-03-31

Grant: Close

Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Secondary Prevention of Kidney Stones: a Randomized, Double-blind, Crossover Trial

Open Date: 2023-10-01

Close Date: 2026-10-01

Articles (38)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (34)

Manuel Andreas Anderegg

University Hospital of Bern

SWITZERLAND

Daniel G Fuster

Research Interests

Make your next move.

Explore related searches

About

Recent Grants

Articles (38)

Magnesium and kidney stones: a concise narrative review

Structure of NHE6 and its lipid-mediated interactions regulating endosomal pH

Transferrin-dependent uptake and distribution of iron in osteoclast-like cells

Long-term citrate treatment in high-risk kidney stone formers is not associated with metabolic adverse effects

Deep biochemical phenotyping reveals prognostic value of rare genetic variants in adult kidney stone disease

Identifying recurrent stone formers with machine learning: A single‐centre observational study

Epidemiology and risk factors of urolithiasis: insights from SKIPOGH, a population-based cohort study in Switzerland

Bone Phenotype in Autosomal Dominant Polycystic Kidney Disease

Renal metabolic defects in patients with recurrent unilateral Nephro- and ureterolithiasis: insights from individual renal unit sampling

Nephrectomy in Autosomal Dominant Polycystic Kidney Disease: A consensus statement of the ERA Genes &amp; Kidney Working Group

Incidental findings on non-contrast abdominal computed tomography in an asymptomatic population: Prevalence, economic and health implications

Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial

Kidney stone disease: risk factors, pathophysiology and management

PIP2-mediated oligomerization of the endosomal sodium/proton exchanger NHE9

Hydrochlorothiazide and Bone Mineral Density in Patients with Kidney Stones: Post Hoc Analysis of the NOSTONE Trial.

SMART Stone Multidisciplinary Team (MDT) and patient care: recommendations for the adult high-risk kidney stone patient pathway

Acid excretion is impaired in calcium oxalate stone formers

Estimating 24-hour urine phosphate excretion from spot urine

A homology-based 3D model and structure–function studies reveal key elements for divalent metal ion transporter ZIP8 (SLC39A8) function

Partial volume effect on kidney stones and lung nodules in CT imaging

Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study.

Indapamide or chlorthalidone to reduce urine supersaturation for secondary prevention of kidney stones: protocol for a randomised, double-blind, cross-over trial (INDAPACHLOR).

Adenine phosphoribosyltransferase deficiency as a rare cause of rapidly progressive chronic kidney disease.

Prevalence and characteristics of genetic disease in adult kidney stone formers

Risk Factors of Asymptomatic Kidney Stone Passage in Adults with Recurrent Kidney Stones

Effects of thiazides and new findings on kidney stones and dysglycemic side effects

Acid excretion is disturbed in calcium oxalate and calcium phosphate stone formers in the Swiss kidney stone cohort

Metformin's Role in Hyperlactatemia and Lactic Acidosis in ICU Patients: A Systematic Review.

Thiazides Attenuate Insulin Secretion Through Inhibition of Mitochondrial Carbonic Anhydrase 5b in β-Islet Cells in Mice

Differences in the Food Consumption Between Kidney Stone Formers and Nonformers in the Swiss Kidney Stone Cohort.

The Swiss Kidney Stone Cohort: A Longitudinal, Multicentric, Observational Cohort to Study Course and Causes of Kidney Stone Disease in Switzerland

Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.

Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence

The role of urinary supersaturations for lithogenic salts in the progression of autosomal dominant polycystic kidney disease

Routine Urinary Biochemistry Does Not Accurately Predict Stone Type Nor Recurrence in Kidney Stone Formers: A Multicentre, Multimodel, Externally Validated Machine-Learning Study

Physiological and Molecular Function of the Sodium/Hydrogen Exchanger NHA2 (SLC9B2)

The role of urinary supersaturations for lithogenic salts in the progression of autosomal dominant polycystic kidney disease

Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients

Collaborators (34)

Manuel Andreas Anderegg

Malgorzata Debowska

Magdalena Jankowska

Remy Bruggmann

Adrian Thomas Huber

Michael Mayr

Giovambattista Capasso

Carla Kirschbaum

Haruna Kawano

Menno Pruijm

Stephan Wüest

Isabel Rubio-Aliaga

Ivan Ivanovski

Carsten A Wagner

Maria Vanessa Perez-Gomez

Gregoire Wuerzner

Tomasz Łukaszuk

Jean-Louis Reymond

Matthias B. Moor

Peter Stenvinkel

Marie Roumet

Jan Halbritter

Alexander Ritter

Abdul Rashid Tony Qureshi

Gergely Gyimesi

Bengt Lindholm

Beat Roth

Mathias Haarhaus

Christian Bucher

Bruno Vogt

Verena Obmann

Angeline Chatelan

Osasuyi Iyasere

Joerg C. Schefold

Nephrectomy in Autosomal Dominant Polycystic Kidney Disease: A consensus statement of the ERA Genes & Kidney Working Group